White Pine Capital LLC bought a new stake in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI – Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 497,186 shares of the company’s stock, valued at approximately $2,143,000. White Pine Capital LLC owned 0.81% of TriSalus Life Sciences at the end of the most recent reporting period.
Other large investors have also modified their holdings of the company. State Street Corp raised its holdings in shares of TriSalus Life Sciences by 86.3% in the second quarter. State Street Corp now owns 610,963 shares of the company’s stock worth $2,780,000 after buying an additional 282,943 shares during the period. BlackRock Inc. bought a new stake in shares of TriSalus Life Sciences during the 2nd quarter worth approximately $12,099,000. Nantahala Capital Management LLC purchased a new position in TriSalus Life Sciences during the 2nd quarter valued at $4,550,000. First Light Asset Management LLC boosted its holdings in TriSalus Life Sciences by 29.3% during the 2nd quarter. First Light Asset Management LLC now owns 6,552,491 shares of the company’s stock valued at $29,814,000 after acquiring an additional 1,485,664 shares during the period. Finally, Bank of New York Mellon Corp purchased a new position in TriSalus Life Sciences during the 2nd quarter valued at $507,000. Hedge funds and other institutional investors own 2.58% of the company’s stock.
Wall Street Analyst Weigh In
Several brokerages have commented on TLSI. Zacks Research raised TriSalus Life Sciences to a “hold” rating in a research report on Thursday, September 10th. Weiss Ratings reiterated a “sell (e+)” rating on shares of TriSalus Life Sciences in a research report on Wednesday, November 4th. Wall Street Zen downgraded TriSalus Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, November 7th. Canaccord Genuity Group lowered their target price on shares of TriSalus Life Sciences from $7.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, November 10th. Finally, Citigroup restated a “buy” rating on shares of TriSalus Life Sciences in a report on Tuesday, November 10th. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, TriSalus Life Sciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.20.
Check Out Our Latest Stock Report on TLSI
TriSalus Life Sciences Stock Performance
Shares of NASDAQ:TLSI opened at $2.43 on Monday. The company has a debt-to-equity ratio of 47.60, a quick ratio of 3.86 and a current ratio of 4.22. The firm has a market cap of $149.64 million, a PE ratio of -4.96 and a beta of 0.50. The firm’s 50 day simple moving average is $4.05 and its 200-day simple moving average is $4.29. TriSalus Life Sciences, Inc. has a one year low of $2.20 and a one year high of $7.95.
TriSalus Life Sciences (NASDAQ:TLSI – Get Free Report) last announced its quarterly earnings data on Tuesday, November 10th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The company had revenue of $12.88 million during the quarter, compared to the consensus estimate of $14.02 million. As a group, equities analysts predict that TriSalus Life Sciences, Inc. will post -0.62 EPS for the current year.
TriSalus Life Sciences Company Profile
TriSalus Life Sciences is a medical technology and oncology company developing ways to improve the delivery of treatments to solid tumors. Its Pressure-Enabled Drug Delivery (PEDD) platform is designed to increase the distribution of therapeutic agents within tumor tissue by using controlled pressure during infusion. The company’s TriNav® infusion system is designed to deliver therapies to the liver through the hepatic artery. TriSalus is also developing PEDD-based approaches for liver and pancreatic tumors, including use with its investigational immunotherapy SD-101, a toll-like receptor 9 agonist.
Featured Articles
- Five stocks we like better than TriSalus Life Sciences
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for TriSalus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TriSalus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
